Iron Homeostasis and Liver Diseases.
4 affiliations
- 1School of Life Sciences, Yunnan Key Laboratory of Cell Metabolism and Diseases, Yunnan University, Kunming, Yunnan, China.
- 2Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
- 3Southwest United Graduate School, Kunming, Yunnan, China.
- 4Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan, China.
Abstract
Iron is an essential micronutrient whose ability to cycle between ferric (Fe³⁺) and ferrous (Fe²⁺) states makes it crucial for physiological processes, including oxygen transport, DNA synthesis, and oxidative phosphorylation. However, because both deficiency and excess can cause severe pathology, precise regulation is critical. The liver plays a central role in systemic iron metabolism, and growing evidence identifies hepatic iron dyshomeostasis as a key catalyst in diverse liver disorders, including metabolic dysfunction-associated steatotic liver disease (MASLD/MASH), alcoholic liver disease, liver fibrosis, and hepatocellular carcinoma (HCC). Hepatic iron accumulation promotes liver injury primarily through oxidative stress, mitochondrial dysfunction, and ferroptosis. In this review, we synthesize the multi-layered regulatory landscape of hepatic iron homeostasis, encompassing systemic coordination, cellular fine-tuning, and epigenetic modifications. We thoroughly dissect the pathogenic impact of iron overload and critically evaluate emerging therapeutic strategies aimed at restoring iron balance, such as hepcidin mimetics and ferroptosis modulators. Finally, we discuss current literature gaps-including preclinical model limitations, the lack of standardized non-invasive biomarkers, and drug delivery bottlenecks-providing a clear roadmap for future translational research in iron-related liver pathologies.
Related
- Iron Supplementation and Copper Homeostasis: Evidence for Potential Copper Depletion, Biomarker Challenges, and Clinical Implications
- Association of Iron Homeostasis With One‐Year All‐Cause Mortality Among Intensive Care Unit Patients with Atrial Fibrillation: A Retrospective Study
- Insight of the role of mitochondrial iron homeostasis in insulin resistance
- Iron homeostasis at the interface of nutrition, infection, and iron supplementation
- An iron compass in the liver: superparamagnetic macrophages give homing pigeons a magnetic sense.
BibTeX
@article{yang2026iron,
title = {{Iron Homeostasis and Liver Diseases.}},
author = {Peng Yang and Zhitian Shi and Qin Huang and Zhihong Tu and Yue Sun and Lin Wang and Yonglong Wei},
journal = {Journal of cellular and molecular medicine},
year = {2026},
month = oct,
doi = {10.1111/jcmm.71412},
url = {https://europepmc.org/article/MED/42908131},
note = {CC BY},
}
RIS
TY - JOUR
TI - Iron Homeostasis and Liver Diseases.
AU - Peng Yang
AU - Zhitian Shi
AU - Qin Huang
AU - Zhihong Tu
AU - Yue Sun
AU - Lin Wang
AU - Yonglong Wei
PY - 2026
DA - 2026/10/01
JO - Journal of cellular and molecular medicine
DO - 10.1111/jcmm.71412
UR - https://europepmc.org/article/MED/42908131
AB - Iron is an essential micronutrient whose ability to cycle between ferric (Fe³⁺) and ferrous (Fe²⁺) states makes it crucial for physiological processes, including oxygen transport, DNA synthesis, and oxidative phosphorylation. However, because both deficiency and excess can cause severe pathology, precise regulation is critical. The liver plays a central role in systemic iron metabolism, and growing evidence identifies hepatic iron dyshomeostasis as a key catalyst in diverse liver disorders, including metabolic dysfunction-associated steatotic liver disease (MASLD/MASH), alcoholic liver disease, liver fibrosis, and hepatocellular carcinoma (HCC). Hepatic iron accumulation promotes liver injury primarily through oxidative stress, mitochondrial dysfunction, and ferroptosis. In this review, we synthesize the multi-layered regulatory landscape of hepatic iron homeostasis, encompassing systemic coordination, cellular fine-tuning, and epigenetic modifications. We thoroughly dissect the pathogenic impact of iron overload and critically evaluate emerging therapeutic strategies aimed at restoring iron balance, such as hepcidin mimetics and ferroptosis modulators. Finally, we discuss current literature gaps-including preclinical model limitations, the lack of standardized non-invasive biomarkers, and drug delivery bottlenecks-providing a clear roadmap for future translational research in iron-related liver pathologies.
SN - 1582-1838
SN - 1582-4934
ER -